Please assess the completion status of the following clinical trial:

Trial Title: A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adolescents and preadolescents with no prior sexual history~Exclusion Criteria:~* Subjects with compromised immune system or have a history of severe allergic reaction

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- qHPV Vaccine in Base Study (Type: EXPERIMENTAL): Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6.
- Placebo in Base Study (Type: PLACEBO_COMPARATOR): Represents participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo at Day 1, Month 2, and Month 6.
- qHPV Vaccine in Extension Study (Type: EXPERIMENTAL): Represents participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.

Based on this trial design, predict the completion outcome and termination type (if applicable).